文献速递青光眼

长期口服硝酸酯类药物与高眼压症及开角型青光眼风险的关联

Association Between Chronic Oral Nitrate Use and the Risk of Ocular Hypertension and Open-Angle Glaucoma.
PubMed 文献 · Am J Ophthalmol · 2025-07-18

本研究基于TriNetX美国协作网络2005年1月1日至2023年1月1日数据,纳入年龄≥40岁、诊断为慢性缺血性心脏病的患者,比较口服硝酸酯类(≥4次续方)与无硝酸酯处方两组。倾向评分匹配后每组各30937例,硝酸酯使用与3年和5年开角型青光眼及原发性开角型青光眼风险降低相关,与高眼压症无显著关联,且需一线青光眼治疗的可能性更低。

要点

  • 倾向评分匹配后每组各30937例,硝酸酯使用与5年开角型青光眼风险降低相关(aHR 0.68)。
  • 硝酸酯使用与5年原发性开角型青光眼风险降低相关(aHR 0.67)。
  • 硝酸酯使用与各时间点高眼压症风险均无显著关联。

核心结论

  • 长期随访中,口服硝酸酯使用与开角型青光眼和原发性开角型青光眼风险降低相关,而对高眼压症发生未见效应。

研究设计与样本

  • 回顾性临床队列研究,数据来自TriNetX美国协作网络2005年1月1日至2023年1月1日。
  • 纳入年龄≥40岁、诊断为慢性缺血性心脏病的患者,分为口服硝酸酯(≥4次续方,索引事件)组与无硝酸酯处方组。
  • 排除既往诊断为青光眼或高眼压症者,以及因缺血性心脏病以外适应症使用硝酸酯者。
  • 采用倾向评分匹配(1:1最近邻,卡钳值0.1)平衡人口学、临床和社会经济因素,匹配后每组各30937例。
  • 采用Cox比例风险模型计算调整风险比(aHR)及95%置信区间(CI)。

主要发现

  • 硝酸酯使用与3年开角型青光眼风险降低相关(aHR 0.82;95%CI 0.71-0.95),5年同样降低(aHR 0.68;95%CI 0.58-0.79)。
  • 硝酸酯使用与3年原发性开角型青光眼风险降低相关(aHR 0.78;95%CI 0.67-0.92),5年同样降低(aHR 0.67;95%CI 0.57-0.79)。
  • 硝酸酯使用与高眼压症风险在各时间点均无显著关联。
  • 硝酸酯组需一线青光眼治疗的可能性在1年(aHR 0.72;95%CI 0.63-0.81)、3年(aHR 0.78;95%CI 0.71-0.85)和5年(aHR 0.83;95%CI 0.75-0.91)均更低。

关键数值与推荐

  • 主要终点为索引事件后1年、3年、5年随访期间开角型青光眼、原发性开角型青光眼、高眼压症的发生风险及一线青光眼治疗的启动。
  • 硝酸酯暴露定义为口服硝酸酯≥4次续方。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the association between the use of oral nitrates and the risk of developing ocular hypertension (OHT) and open-angle glaucoma (OAG) in patients with chronic ischemic heart disease (IHD). DESIGN: Retrospective clinical cohort study. SUBJECTS: Patients aged ≥40 with a diagnosis of chronic IHD identified in the TriNetX U.S. Collaborative Network from January 1, 2005, to January 1, 2023 METHODS: This study utilized deidentified patient data from the TriNetX database. Patients aged ≥40 years with a diagnosis of chronic IHD were categorized into two cohorts: those prescribed oral nitrates (≥4 renewal prescriptions) (index event) and those without nitrate prescriptions. Exclusion criteria included a prior diagnosis of glaucoma or OHT or those who had nitrates for indications other than IHD. Propensity score matching (PSM) (1:1 nearest neighbor, caliper 0.1) was performed to balance demographic, clinical, and socioeconomic factors. We performed Cox proportional hazards model to calculate the adjusted hazards ratio (aHR) and 95% confidence intervals (CIs).The primary endpoints were the risks of developing OAG, primary open-angle glaucoma (POAG), OHT, and the initiation of first-line glaucoma treatments over 1-, 3-, and 5-year follow-up periods from the index event. MAIN OUTCOME MEASURES: OAG, POAG, OHT, and the initiation of first-line glaucoma treatments. RESULTS: After PSM, each cohort included 30,937 patients. Nitrate use was associated with a significantly lower risk of OAG at 3 years (aHR, 0.82; 95% CI, 0.71-0.95) and 5 years (aHR, 0.68; 95% CI, 0.58-0.79). Similarly, the risk of POAG was reduced at 3 years (aHR, 0.78; 95% CI, 0.67-0.92) and 5 years (aHR, 0.67; 95% CI, 0.57-0.79). However, no significant association was observed between nitrate use and OHT at any time point. Patients in the nitrate group were also less likely to require first-line glaucoma therapy at 1 year (aHR, 0.72; 95% CI, 0.63-0.81), 3 years (aHR, 0.78; 95% CI, 0.71-0.85), and 5 years (aHR, 0.83; 95% CI, 0.75-0.91). CONCLUSIONS: The use of oral nitrates was associated with a reduced risk of OAG and POAG over long-term follow-up, while no effect was observed on OHT development.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Elhusseiny AM, Eleiwa TK, Darwich R, et al. Association Between Chronic Oral Nitrate Use and the Risk of Ocular Hypertension and Open-Angle Glaucoma. Am J Ophthalmol. 2025. PMID: 40684969. doi:10.1016/j.ajo.2025.07.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。